Evidence map›Paper›PMID 42877184›Full record

ArticleArchives of medical science : AMS2026

Development of tRNA-based biomarkers for breast cancer: insight from machine learning.

Quan Yuan, Rongjie Ye, Hao Yu, Ge Yu, Ming Niu

Abstract read
In one paragraph

Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Quan YuanHarbin Medical University Cancer Hospital, Harbin, China.
Rongjie YeFujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, Fujian, China.
Hao YuThe First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Ge YuHarbin Medical University Cancer Hospital, Harbin, China.
Ming NiuHarbin Medical University Cancer Hospital, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Breast cancer (BC) is one of the most frequent cancers in women globally. Research on tRNA-related biomarkers for predicting BC survival remains notably lacking. In this study, bioinformatics analysis was used to identify tRNA-related gene targets. Material and methods: We obtained closely related mRNAs by screening BC prognosis-associated tRNAs from the OncotRF database. Next, we selected prognostically important mRNAs further using the Bruta algorithm. We developed a risk model based on these significant genes by using a variety of machine learning techniques and validated the expression experimentally. Data from the TCGA, GEO, and IMvigor210 datasets were used to validate the predictive efficacy of the t-mRNA characteristics. We also obtained the single-cell RNA sequencing (scRNA-Seq) data from the TISCH2 database and the RNA-Seq data from the UCSC Xena database for pan-cancer analysis. Results: We created a prognostic model with 12 t-mRNAs associated with BC. Strong predictive performance of this model was demonstrated by nomogram, ROC and survival analyses. Functional enrichment analysis revealed differences between the low-risk and high-risk groups in immunological-related biological processes. The high-risk group showed reduced immunotherapy efficiency and greater M2 macrophage infiltration, according to the analysis of immune infiltration and immunotherapy responsiveness. Furthermore, the pan-cancer investigation revealed that high-risk tumors typically exhibit more aggressive features. We also found differential expression of model genes between normal and cancer cells. Conclusions: We created a t-mRNA model that may accurately predict the prognosis of BC patients and promote the development of precision medicine for cancer.

Indexed as

breast cancerimmunotherapymachine learningpan-cancer analysisprognosistRNA

Identifiers

PMID42877184
PMCPMC13663647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.